Dupilumab

biologic · respiratory · integumentary · immune-hematologic · Subcutaneous

Dupilumab, a biologic. Fully human IgG4 mAb binding IL-4Rα subunit shared by IL-4 + IL-13 receptors → blocks both Th2 cytokines.… Subcutaneous half-life 21 d.

Fully human IgG4 mAb binding IL-4Rα subunit shared by IL-4 + IL-13 receptors → blocks both Th2 cytokines. Paradigm-shifting treatment for atopic dermatitis — moderate-severe AD failed every prior systemic, dupilumab clears ~40% and improves 70–80%. Expanded to asthma, CRSwNP, EoE, prurigo nodularis.

PK: ABSORPTION RATE AUTHORED FROM OPEN-ACCESS FULL TEXT (PMC7496261). This row carried no ka, so the solver substituted 1.0/h and put the peak at 6.6 h. Verbatim: "The concentration-time profiles of the dupilumab 150- and 300-mg SC doses ... with peak drug concentrations being achieved on average at 3-7 days after dosing" — the therapeutic dose range. RANGE: the shorter endpoint is taken. A second open-access paper corroborates it independently at "t max was 4-8 days" for weight-based dosing. With the stored half-life fixing ke, Tmax solves uniquely for ka by inverting the model own definition, ln(ka/ke)/(ka-ke) = Tmax — ARITHMETIC, NOT AN ESTIMATE — giving 0.05176/h, which reproduces 72 h on substitution. EXPOSURE IS UNCHANGED: the absorption rate cancels out of AUC, so only the shape moves.

Pharmacokinetics

• Subcutaneous — t½ 21.0 d · F 64% · ka 0.05176 h⁻¹ · Vd 4.9 L

Sources: PMID:27690741, PMID:32348036